Member Info for Romeike

Bonkers. It will add 4-5k boepd I beleive.

The mind boggles at what this means exactly!

I feel sorry for capricon holders in the pocket of hedgies looking to screw over retail at every turn by chashing in on uncertainty that they themselves are causing.

NewMed Energy LP says it continues to promote its proposed merger with Capricorn Energy on the existing terms, saying this is the "most compelling option for all relevant stakeholders". However, the Israeli firm also continues to consider "alternative strategic options" to the merger with Capricorn, which is facing pushback on the deal from shareholder Palliser Capital Master Fund Ltd.

https://www.independent.ie/business/irish/fund-that-killed-tullow-oil-merger-deal-is-now-trying-to-undo-its-replacement-42231588.html

Ghana has more gas than it knows what to do with and yet it still imports vast quantities of energy products from Nigeria. I think we all know what the real problem is.

On the one hand they are delivering, over-delivering really, on Jubliee. But on TEN I remain very concerned. I am going to take some time to go back and get a good idea of the TEN development plan as we are clearly behind due to the two Ntomme wells not providing the hoped for results.

The idea that Pfizer and GSK are going to "dump" quality Haleon shares on the market, thus destroying their ability to get decent value out of those share is ridiclous. The quality of the financial media is a joke sometimes. Pfizer and GSK clearly both said they will reduce their holdings slowly to maximise value. This implies the rate will be such that it will be a small % of average daily volume and therefore will not impact the price.

And so the downward pressure on the SP to scupper the CNE deal is revealed

The rushed potential merger between CNE and NewMed is far from solidified and remains tenuous. CNE have said they withdrew their recommendation sure, but the continued RNS suggestes they are trying to keep the bridge open in case NewMed has a change of heart. New Med's offer does appear rather impulsive after all. I don't particularly like the look of what CNE has to offer, but the cash would lowered Tullows risk. Whether that is actually worth it should a Kenya sale go ahead is a different story.

Early guidance for FY22 was 55-61, but based on information so for approx 63 seems likely for FY22, that is what I am hoping for anyway. Tullow is at the bottom of a U-shaped production turn around. A lot of investment was put in this year to set the ground for production growth next year, not simply offsetting declines. 24/25 will see even more production growth.

The only reason debt didn't fall was because they opted to lay out 126 million on additional Jubilee barrels, which looks to have been a solid play as it is paying for itself very quickly. Hoping approx 3 billion from sale of most or all of Kenya stake will sort everything.

The NewMed Energy deal offers far less potential for a few pence more up front. People thinking Tullow will offer more are dreaming. Take the cash and run.

I for one am glad if the news about Capricon is true because I actually think the deal offered them far too much upside in return for a small amount of upfront cash that Tullow can do without so long as oil prices remain high. I also didn't like the look of the latest Capricorn trading statements re: production and they are too gas heavy.

It amazes me the ignorant posts here re: figures. You guys realise the figures are rather strong, you have to factor in that they bought in production that is rapidly paying for itself, and there was the arbitrated payout too. Not least production is on track, under control and by full year we ought to be firmly back on the path to real production growth rather than recovery to past averages. News on Kenya will hopefully provide a further boost in the months to come, and I expect will secure the interest of Capricon as the benefits of the deal could not be clearer. For Tullow the deal frees up interest payments redirect to accelerating production projects.

The socialists want Tullow to be forced to use only Ghanaian labour, not the best labour regardless of background. The fact is that Tullow provides substanital numbers of jobs and training to Ghanians but production already suffered in the past because Tullow needs to employ the RIGHT SKILLS and these need to come from whereever necessary to get the best outcome. Placing severe limitations on Tullow's ability to optimise its business is not good for Tullow and provides a worse result for Ghana.

It's hilarious how scared people are of a few ambulance chasers. Frankly I think it is disgusting how these American parasites corral thousands of vulnerable people walking out of hospital oncology departments, most of whom possibly never heard of Zantac in their life, to sign up to these farcical, unprovable class actions on the off-chance they are paid to go away. The saddest thing is the patients will get cents in the dollar for any settlements as the legal sharks do what sharks do. More than 14 independent studides into this issue show zero link between the impurity and cancer distinguishable from that resulting by background radation. In other word there's no link. GSK woud be mad to settle with these sharks, show them the road with a big boot.

Palliser Capital needs to shut up. It doesn't give a toss about shareholders.

Re: Kenya deal value, while a figure of approx 3bn USD has been mentioned it is not clear how much of Tullow's stake this buys. India will want to lead with the largest stake so will buy at leat 30%, leaving Tullow with 20% or less. But at 3Bn with the buyer both huge state-backed refiners, and therefore guaranteed buyers of potentially all the barrels produced, this could be a very good deal beyond the immediate financial gain. I expect Tullow will retain a 10-20% stake, as keeping their expertise and local knowledge will be desirable for the partners. Some of the other partners may also farm down, providing India an overal 50%+ stake. It is possible Dhir will sell the entire stake, but I think if this happens it will be because he has his eye on an aquisition elsewhere. Increasingly impressed with this CEO, he's made a number of very shrewd moves and Capricon's enthusiasm for a deal arguably weighted to Tullow is making more sense in light of the Kenya developments.

In the context of the 50bn offer from Unilever - very dissapointing, no actually annoying - to see the world's largest independent consumer healthcare firm list on list at a palty market cap of just 31bn. Even accounting for Haleon taking on the extra debt from GSK this makes the decicision to reject the bid a bad move for investors.

I can't be the only one wanting to know if this loss is covered under operational risk insurance. I certainly beleive they would be making a claim. They had security in place etc. so the fault for the loss is not woth Goldstone and the loss adjustor can be used to support the claim.